ERBB2 and cancer: Previous studies have suggested that younger women develop cancers with more aggressive biological features and are more commonly diagnosed with larger tumors, lymphatic metastasis, higher grade disease, estrogen receptor-negative tumors, and over-expression of the human epidermal growth factor receptor 2 (HER2)5, 10.